The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

Companies News

Pharmacy company MEDA acquires a US respiratory company

Friday, 30 August 2013
Pharmacy company, Meda announced that it has signed an agreement to acquire the US development company Acton Pharmaceuticals, Inc. (“Acton”) including the proprietary product Aerospan.

Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide. The product is approved by the FDA and has shown in clinical studies to have a high deposition of active drug in the airways as a result of a built-in inhalation chamber (called a “spacer”).

In a randomized double-blind placebo-controlled study, published in the Annals of Allergy, Asthma & Immunology, Aerospan show no significant negative effect on linear growth in children with asthma. This is an important feature of the Aerospan product. FDA has recently approved the addition of data from this study in the prescribing information.

Print Friendly and PDF